PharmiWeb.com - Global Pharma News & Resources
10-Jun-2021

Alacare® (5-aminolevulinic acid) medicated plaster for Actinic Keratosis approved for use within Scotland

Alacare® medicated plaster for Mild Actinic Keratoses Lesions has been approved for use in Scotland by the Scottish Medicines Consortium1. It is the first photodynamic therapy plaster for mild Actinic Keratosis.

Conor Cronin, Product Manager for Alacare® comments, “I am delighted that healthcare professionals in Scotland will have access to this very convenient method of applying 5-ALA to their patients, especially those who may have lesions in difficult to treat areas.”

Alacare® is available to buy from Alloga.

About Actinic Keratosis:

Actinic Keratosis lesions are patches of dry and scaly skin that develop slowly after over exposure to the sun. They are mostly found on the face, lips, ears scaly, back and the back of patients’ hands. If lesions are not treated a small percentage of them may develop into Squamous Cell Carcinomas (a type of skin cancer)2.

About Alacare®:

Alacare® is the first photodynamic therapy plaster indicated for single use treatment of mild actinic keratosis (AK).

Once an Alacare® plaster is positioned over an Actinic Keratosis lesion patients are able to carry on their day as normal for 4 hours while the active ingredient (5-ALA) is absorbed. After this the plaster is removed and the lesion is treated with red light therapy which causes the AK cells to die.  

For further information on Alacare®, please visit www.alacareuk.co.uk

References

  1. https://www.scottishmedicines.org.uk/medicines-advice/5-aminolevulinic-acid-alacare-abb-smc2353/
  2. http://www.pcds.org.uk/clinical-guidance/actinic-keratosis-syn.-solar-keratosis
Alacare® (5-aminolevulinic acid) medicated plaster for Actinic Keratosis approved for use within Scotland

Editor Details

Related Links

Last Updated: 11-Jun-2021